BOLD-MRI for Liver Cancer

(BOLDMRI Trial)

ML
KB
Overseen ByKaila Brustkern
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: UNC Lineberger Comprehensive Cancer Center
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

The purpose of this study is to find out whether a special type of magnetic resonance imaging ( MRI), called blood oxygen level-dependent (BOLD) MRI, can help measure how much oxygen is present in liver tumors. Tumors with low oxygen levels are described as being hypoxic.

Yttrium-90 (Y-90) is a type of radioactive material used to treat liver tumors, including hepatocellular carcinoma (HCC), a type of liver cancer. Y-90 is a form of radiation treatment delivered directly to liver tumors through tiny beads carried by blood vessels. These beads release radiation that damages and kills cancer cells while helping limit radiation exposure to surrounding healthy tissue. This treatment is also called Y-90 radioembolization or selective internal radiation therapy (SIRT).

Who Is on the Research Team?

BH

Bryan Harris, MD

Principal Investigator

UNC Lineberger Comprehensive Cancer Center

AV

Alexander Villalobos, MD

Principal Investigator

UNC Lineberger Comprehensive Cancer Center

Are You a Good Fit for This Trial?

This trial is for people with liver cancer, specifically hepatocellular carcinoma. Participants should be candidates for Y-90 radioembolization treatment and able to undergo MRI scans. Detailed inclusion or exclusion criteria are not provided.

Inclusion Criteria

I am 18 years old or older.
Life expectancy ≥6 months as determined by the investigator
I have a tumor at least 2 cm that may benefit from Y90 radioembolization.
See 2 more

Exclusion Criteria

My cancer has spread to other parts of my body.
Definite liver transplant candidate
I currently have another type of cancer besides my main diagnosis.

What Are the Treatments Tested in This Trial?

Interventions

  • Yttrium-90 (Y-90) Radioembolization

Trial Overview

The study uses a special MRI scan (BOLD-MRI) to measure oxygen levels in liver tumors before Y-90 radioembolization treatment, aiming to see if this imaging can predict how well the tumor will respond to therapy.

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: Hepatocellular carcinomaExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

UNC Lineberger Comprehensive Cancer Center

Lead Sponsor

Trials
377
Recruited
95,900+